Repairing the Inner Ear to Restore Hearing

Edited and Approved by Stephen C. Rose, PhD, MS

For someone who struggles to follow conversation, hearing restoration is more than a better score on a test. It means participating more easily in daily life. Regenerative medicine aims to recover the biology that makes hearing possible. The central challenge is that hearing loss has different causes, and each requires a different repair.

The evidence now includes genuine hearing improvements from gene therapy for a rare inherited disorder. Growing replacement sensory cells and rebuilding auditory nerves for common acquired hearing loss remain experimental. Understanding that distinction helps explain both the excitement and the limits of current research. [1] [2] [3]

What needs to be repaired

Sound sets the eardrum and tiny middle-ear bones vibrating. Those vibrations reach the cochlea, the fluid-filled spiral of the inner ear. Microscopic projections on sensory hair cells bend, producing electrical changes. The auditory nerve carries information onward, and the brain interprets it as sound. These cells are called hair cells because of their projections; they are unrelated to hair on the head. [4]

This sequence gives researchers several possible targets. A treatment might replace missing sensory cells, restore their communication with nerves, or replenish damaged nerve cells. Correcting one component will not necessarily repair damage elsewhere.

Age-related hearing loss can involve changes in the inner ear and nerve pathways, with contributions from accumulated noise exposure and other conditions. It therefore differs from a disorder caused by one defective gene. Hearing aids make sounds louder; cochlear implants bypass damaged sensory structures and stimulate the auditory nerve. They provide useful rehabilitation without regenerating cells. [5] [6]

Growing new sensory cells

Some animals, including birds and fish, naturally replace damaged hair cells. The mature mammalian cochlea does not normally do this. Researchers have consequently studied supporting cells, neighboring cells that may remain after sensory cells die, as a potential source of replacements. Reprogramming means changing which genes a cell uses so that it adopts another identity. [2]

A 2023 mouse study combined small molecules and short RNA molecules with delivery of Atoh1, a gene involved in hair-cell development. The approach produced hair-cell-like cells in the adult cochlea after hair-cell loss. This demonstrated a route toward cellular replacement, rather than restored hearing in patients. [7]

The distinction matters because the new cells were immature, and their long-term survival was unresolved. A useful replacement must mature, survive, and occupy a position where its projections can respond to mechanical movement. The investigators also identified injury from their delivery procedure as a problem requiring improvement. Their paper presented reliable hearing restoration in deaf adult animals as a future goal. [7]

Simply finding cells with hair-cell markers is therefore an early milestone. The practical question is whether those cells contribute to durable hearing. A successful treatment must preserve the remaining machinery while adding functional replacements.

What a human regeneration trial found

The REGAIN trial tested LY3056480, a drug intended to encourage hair-cell regeneration by inhibiting Notch signaling, a system involved in determining cell identity. Adults received injections through the eardrum. The initial safety phase included 15 participants; the subsequent phase included 44. [8]

The trial did not meet its main hearing-improvement endpoint at 12 weeks. Average secondary measures, including speech reception, also did not improve. Some individuals showed favorable changes, but the study was open-label and lacked a placebo group. Those observations cannot establish treatment efficacy. [8]

This result does not rule out every regeneration strategy. It does show why a plausible mechanism and acceptable short-term tolerability are insufficient. Human trials must demonstrate a meaningful benefit, using comparisons that distinguish treatment effects from ordinary variation in testing.

Restoring a genetic communication defect

OTOF-related deafness offers a different opportunity. The affected gene encodes otoferlin, a protein needed for sensory cells to communicate with the auditory nerve. Gene therapy supplies instructions for producing that protein in surviving cells. It repairs a signaling defect instead of growing replacement hair cells. [1]

In the published DB-OTO trial, nine of 12 children met the main hearing target at 24 weeks, and three achieved average normal hearing sensitivity. The study was a small, open-label trial with a single treatment group. Its results nevertheless demonstrated substantial improvement in this specifically defined disorder. [1]

A separate 2026 study of another OTOF gene-therapy product included 42 participants, ranging from infancy to adulthood, with follow-up extending to 2.5 years for some participants. Hearing improved in 90%, with younger participants generally improving more than adults. This study also had no randomized comparison group; reported adverse events included a severe reduction in neutrophils, a type of white blood cell. [9]

On April 23, 2026, the FDA granted accelerated approval to Otarmeni, the therapy studied as DB-OTO. Eligibility is narrow: severe-to-profound or profound hearing loss associated with confirmed defects in both OTOF gene copies, preserved outer hair-cell function, and no previous cochlear implant in the treated ear. Continued approval may depend on confirming clinical benefit and durability. [10]

This is an important advance in biological hearing restoration. It does not establish a treatment for ordinary age-related or noise-induced loss. Administration requires inner-ear surgery, and the label describes procedural risks and adverse reactions. Otarmeni has not been studied in people aged 65 or older. [11]

Rebuilding the auditory nerve

Cell transplantation addresses another part of the system. In a foundational experiment, researchers guided human embryonic stem cells into immature cells programmed toward an inner-ear nerve identity. Transplantation into gerbils with experimentally damaged auditory neurons improved sound-evoked electrical responses. The hair cells were relatively preserved in that model. [12]

An electrical response in an animal is meaningful evidence of recovering function, but it is not equivalent to understanding speech. Nor does using human-derived cells make an experiment a human clinical trial.

The registered Rincell-1 study plans to compare a cochlear implant plus an experimental cell therapy with an implant alone in selected adults with neural hearing loss. Its initial focus includes safety. As of September 30, 2026, the registry listed the trial as not yet recruiting, with no posted results. Registration documents a research plan, not demonstrated restoration. [13]

A recent review emphasizes that implanted cells must survive, develop correctly, and establish functional connections. Candidate selection is also difficult: poor performance with an implant can arise from several causes, and no single validated test reliably identifies auditory-neuron degeneration with the specificity needed for trial selection. [3]

How you may be able to benefit

Begin with identifying the kind of hearing problem you have. A hearing assessment can help distinguish loss of sound sensitivity from difficulty understanding speech and guide appropriate referral. If hearing loss began early in life or appears inherited, ask whether genetic evaluation is appropriate. Eligibility for a gene therapy depends on a specific diagnosis, not simply how severe the hearing loss feels. [5] [11]

For gradual hearing difficulties, discuss current rehabilitation rather than waiting for regeneration. Hearing aids, assistive listening systems, and assessment for a cochlear implant can improve access to sound. Implants require training and adjustment; they do not reproduce normal hearing. A quieter setting and having conversation partners face you can also help communication now. [5] [6]

Protect remaining hearing by limiting loud-sound exposure and using suitable ear protection. If hearing drops suddenly, particularly in one ear, seek medical attention immediately. Sudden sensorineural hearing loss is a medical emergency, and delayed assessment can reduce the effectiveness of treatment. This is a different situation from slowly progressive age-related loss. [5] [14]

When considering a regenerative treatment, ask which damaged component it targets and whether benefit has been demonstrated in people with your diagnosis. Look for published human outcomes, adequate follow-up, and a clear regulatory or clinical-trial status. A registry listing or a picture of new cells does not answer those questions by itself.

For healthy aging, preserving communication and daily function already matters. Future regenerative treatments may expand what is possible, but the strongest current lesson is precision: successful hearing restoration requires matching the repair to the actual biological problem.

References

[1] Valayannopoulos V, Bance M, Carvalho DS, et al. DB-OTO Gene Therapy for Inherited Deafness. N Engl J Med. 2026;394(11):1074-1083. doi:10.1056/nejmoa2400521.

[2] McGovern MM, Cox BC. Hearing restoration through hair cell regeneration: A review of recent advancements and current limitations. Hear Res. 2025;461:109256. doi:10.1016/j.heares.2025.109256.

[3] West N, Navntoft CA, Haywood N, et al. Boosting auditory nerve function with cell therapy - status, surgical approach and potential candidates. Hear Res. 2026;481:109806. doi:10.1016/j.heares.2026.109806.

[4] National Institute on Deafness and Other Communication Disorders. How Do We Hear? National Institutes of Health. Updated March 16, 2022. Accessed September 30, 2026.

[5] National Institute on Deafness and Other Communication Disorders. Age-Related Hearing Loss (Presbycusis). National Institutes of Health. Updated March 17, 2023. Accessed September 30, 2026.

[6] National Institute on Deafness and Other Communication Disorders. Cochlear Implants. National Institutes of Health. Accessed September 30, 2026.

[7] Quan YZ, Wei W, Ergin V, et al. Reprogramming by drug-like molecules leads to regeneration of cochlear hair cell-like cells in adult mice. Proc Natl Acad Sci U S A. 2023;120(17):e2215253120. doi:10.1073/pnas.2215253120.

[8] Schilder AGM, Wolpert S, Saeed S, et al. A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss. Nat Commun. 2024;15(1):1896. doi:10.1038/s41467-024-45784-0.

[9] Jiang L, Cheng X, Lv J, et al. Multicentre gene therapy for OTOF-related deafness followed up to 2.5 years. Nature. 2026;653(8116):1170-1177. doi:10.1038/s41586-026-10393-y.

[10] U.S. Food and Drug Administration. FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program. April 23, 2026. Accessed September 30, 2026.

[11] U.S. Food and Drug Administration. OTARMENI Prescribing Information. Revised April 2026. Accessed September 30, 2026.

[12] Chen W, Jongkamonwiwat N, Abbas L, et al. Restoration of auditory evoked responses by human ES-cell-derived otic progenitors. Nature. 2012;490(7419):278-282. doi:10.1038/nature11415.

[13] ClinicalTrials.gov. First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant (NCT07032038). National Library of Medicine. Sponsor-submitted record updated August 11, 2026. Accessed September 30, 2026.

[14] National Institute on Deafness and Other Communication Disorders. Sudden Sensorineural Hearing Loss (SSHL). National Institutes of Health. Updated September 14, 2018. Accessed September 30, 2026.